Elevated BCRP/ABCG2 expression confers acquired resistance to gefitinib in wild-type EGFR-expressing cells.

Elevated BCRP/ABCG2 expression confers acquired resistance to gefitinib in wild-type EGFR-expressing cells.

The sensitivity of non-small cell lung cancer (NSCLC) patients to EGFR tyrosine kinase inhibitors (TKIs) is strongly associated with activating EGFR mutations. Although not as sensitive as patients harboring these mutations, some patients with wild-type EGFR (wtEGFR) remain responsive to EGFR TKIs,...

Full description

Bibliographic Details
Main Authors: Yun-Ju Chen, Wei-Chien Huang, Ya-Ling Wei, Sheng-Chieh Hsu, Ping Yuan, Heather Y Lin, Ignacio I Wistuba, J Jack Lee, Chia-Jui Yen, Wu-Chou Su, Kwang-Yu Chang, Wen-Chang Chang, Tse-Chuan Chou, Chao-Kai Chou, Chang-Hai Tsai, Mien-Chie Hung
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2011-01-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC3121773?pdf=render

Internet

http://europepmc.org/articles/PMC3121773?pdf=render

Similar Items